Cancer drug repurposed to shrink NF1 skin bumps in early trial
NCT ID NCT07102394
First seen Sep 30, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This early-stage study tests if a drug called IMLYGIC, already used for certain skin cancers, can safely treat painful or disfiguring skin bumps (cutaneous neurofibromas) in adults with NF1. Ten participants will receive up to 4 cycles of injections directly into their tumors. The main goals are to see if the treatment is feasible and tolerable, not yet to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NF1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.